Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma
Published in: Blood
Access to document
10.1182/blood-2017-12-822817
document
Anne M R Schrader, Patty M Jansen, Rein Willemze, Maarten H Vermeer, Anne-Marie Cleton-Jansen, Sebastiaan F Somers, J H Hendrik Veelken, Ronald van Eijk, Willem Kraan, Marie José Kersten, Michiel van den Brand, Wendy B C Stevens, Daphne de Jong, Myrurgia Abdul Hamid, Bea C Tanis, Eduardus F M Posthuma, Marcel Nijland, Arjan Diepstra, Steven T Pals, Arjen H G ClevenJoost S P Vermaat
Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma
Published in: Annals of Hematology
Access to document
10.1007/s00277-018-3233-9
document
Marcel Nijland, Tom van Meerten, Annika Seitz, Gerwin Huls, Robby Kibbelaar, Lydia Visser, Anke van den Berg, Arjan Diepstra
Combined loss of HLA I and HLA II expression is more common in the non-GCB type of diffuse large B cell lymphoma
Published in: Histopathology
Access to document
10.1111/his.13445
document
As an immune escape mechanism tumor cells may downregulate expression of Human Leukocyte Antigens (HLA). Loss of HLA class I and class II has been described in various subtypes of diffuse large B cell lymphoma (DLBCL), including the not otherwise specified (NOS) subgroup. 1,2 We analyzed HLA class I and class II expression in DLBCL not otherwise specified (NOS) to investigate whether there is an association between HLA expression, cell of origin (COO) and the recently reported FOXP1 expression in non-GCB DLBCL. 3 This article is protected by...
Relapse in stage I(E) diffuse large B-cell lymphoma
Published in: HEMATOLOGICAL ONCOLOGY
Access to document
10.1002/hon.2487
document
Despite a general favourable outcome in limited stage diffuse large B-cell lymphoma (DLBCL), relapses occur in about 10 to 20% of patients. Prognostic models only partially identify patients at risk for relapse. Moreover, it is not known whether the outcome after such a relapse is similar to the outcome after relapse in advanced stages. From January 2004 through December 2012, all newly diagnosed patients with stage I(E) DLBCL were retrospectively analysed from 2 clinical databases to investigate the relapse pattern and outcome in relation to initial treatment and...
Marcel Nijland, Karin Boslooper, Gustaaf van Imhoff, Robbie Kibbelaar, Peter Joosten, Huib Storm, Eric N van Roon, Arjan Diepstra, Hanneke C Kluin-Nelemans, Mels Hoogendoorn
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens
Published in: Annals of Hematology
Access to document
10.1007/s00277-017-3167-7
document
Burkitt lymphoma is an aggressive B cell malignancy accounting for 1-2% of all adult lymphomas. Treatment with dose-intensive, multi-agent chemotherapy is effective but associated with considerable toxicity. In this observational study, we compared real-world efficacy, toxicity, and costs of four frequently employed treatment strategies for Burkitt lymphoma: the Lymphome Malins B (LMB), the Berlin-Frankfurt-Munster (BFM), the HOVON, and the CODOX-M/IVAC regimens. We collected data from 147 adult patients treated in eight referral centers. Following central Burkitt lymphoma, resulting in the following treatment groups: LMB 36 patients, BFM 19...
L. E. M. Oosten, M. E. D. Chamuleau, F. W. Thielen, L. C. de Wreede, C. Siemes, J. K. Doorduijn, O. S. Smeekes, M. J. Kersten, L. Hardi, J. W. Baars, A. M. P. Demandt, W. B. C. Stevens, M. Nijland, G. W. van Imhoff, R. Brouwer, C. A. Uyl-de Groot, P. M. Kluin, D. de Jong, H. Veelken